Antiviral Resistance and the Control of Pandemic Influenza

Background The response to the next influenza pandemic will likely include extensive use of antiviral drugs (mainly oseltamivir), combined with other transmission-reducing measures. Animal and in vitro studies suggest that some strains of influenza may become resistant to oseltamivir while maintaining infectiousness (fitness). Use of antiviral agents on the scale anticipated for the control of pandemic influenza will create an unprecedented selective pressure for the emergence and spread of these strains. Nonetheless, antiviral resistance has received little attention when evaluating these plans. Methods and Findings We designed and analyzed a deterministic compartmental model of the transmission of oseltamivir-sensitive and -resistant influenza infections during a pandemic. The model predicts that even if antiviral treatment or prophylaxis leads to the emergence of a transmissible resistant strain in as few as 1 in 50,000 treated persons and 1 in 500,000 prophylaxed persons, widespread use of antivirals may strongly promote the spread of resistant strains at the population level, leading to a prevalence of tens of percent by the end of a pandemic. On the other hand, even in circumstances in which a resistant strain spreads widely, the use of antivirals may significantly delay and/or reduce the total size of the pandemic. If resistant strains carry some fitness cost, then, despite widespread emergence of resistance, antivirals could slow pandemic spread by months or more, and buy time for vaccine development; this delay would be prolonged by nondrug control measures (e.g., social distancing) that reduce transmission, or use of a stockpiled suboptimal vaccine. Surprisingly, the model suggests that such nondrug control measures would increase the proportion of the epidemic caused by resistant strains. Conclusions The benefits of antiviral drug use to control an influenza pandemic may be reduced, although not completely offset, by drug resistance in the virus. Therefore, the risk of resistance should be considered in pandemic planning and monitored closely during a pandemic.

[1]  Carl T. Bergstrom,et al.  The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. Ward,et al.  Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. , 2005, The Journal of antimicrobial chemotherapy.

[3]  C. Loveday,et al.  Nucleoside Reverse Transcriptase Inhibitor Resistance , 2001, Journal of acquired immune deficiency syndromes.

[4]  Gavin J. D. Smith,et al.  Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. , 2006, The Journal of infectious diseases.

[5]  R. Kaiser,et al.  Primary HIV Drug Resistance and Efficacy of First-Line Antiretroviral Therapy Guided by Resistance Testing , 2006, Journal of acquired immune deficiency syndromes.

[6]  Ted Cohen,et al.  Isoniazid resistance and the future of drug-resistant tuberculosis. , 2004, Microbial drug resistance.

[7]  Catherine Macken,et al.  Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use , 2006, Antimicrobial Agents and Chemotherapy.

[8]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[9]  V. Miller.  International perspectives on antiretroviral resistance. Resistance to protease inhibitors. , 2001, Journal of acquired immune deficiency syndromes.

[10]  Hideo Goto,et al.  Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.

[11]  M. Lipsitch,et al.  The rise and fall of antimicrobial resistance. , 2001, Trends in microbiology.

[12]  A. Moscona,et al.  Oseltamivir resistance--disabling our influenza defenses. , 2005, The New England journal of medicine.

[13]  M Elizabeth Halloran,et al.  Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups , 2006, Journal of the Royal Statistical Society. Series C, Applied statistics.

[14]  Marc Lipsitch,et al.  Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S Bonhoeffer,et al.  Evaluating treatment protocols to prevent antibiotic resistance. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  V. Miller.  Resistance to Protease Inhibitors , 2001 .

[17]  A. Grant,et al.  Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis , 2006, Emerging infectious diseases.

[18]  A S Perelson,et al.  Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. , 1998, The Journal of infectious diseases.

[19]  A. Monto,et al.  Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. , 2004, The Journal of infectious diseases.

[20]  Sebastian Bonhoeffer,et al.  This PDF file includes: SOM Text , 2022 .

[21]  Strengthening pandemic influenza preparedness and response , 2005 .

[22]  M. Kretzschmar,et al.  Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. , 2006, American journal of epidemiology.

[23]  Ted Cohen,et al.  The effect of drug resistance on the fitness of Mycobacterium tuberculosis. , 2003, The Lancet. Infectious diseases.

[24]  B. Levin,et al.  The biological cost of antibiotic resistance. , 1999, Current opinion in microbiology.

[25]  C. Macken,et al.  Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses , 2005, Antiviral therapy.

[26]  S. Paulous,et al.  Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. , 1996, The Journal of general virology.

[27]  W. J. Bean,et al.  Biologic potential of amantadine-resistant influenza A virus in an avian model. , 1989, The Journal of infectious diseases.

[28]  Anne Moscona.  Oseltamivir-resistant influenza? , 2004, The Lancet.

[29]  Matthew H Samore,et al.  Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. , 2006, American journal of epidemiology.

[30]  R. Webster,et al.  Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. , 2006, Antiviral research.

[31]  Comments from the Center for Biosecurity of UPMC on the National Strategy for Pandemic Influenza: Implementation Plan. , 2006, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[32]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[33]  P. Kaye.  Infectious diseases of humans: Dynamics and control , 1993 .

[34]  Susan Mallett,et al.  A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. , 2003, The Journal of antimicrobial chemotherapy.

[35]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Robins,et al.  Transmissibility of 1918 pandemic influenza , 2004, Nature.

[37]  A. Nizam,et al.  Containing pandemic influenza with antiviral agents. , 2004, American journal of epidemiology.

[38]  N. Cox,et al.  Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. , 2006, JAMA.

[39]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[40]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility , 2005, Antimicrobial Agents and Chemotherapy.

[41]  B. Cissé,et al.  Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial , 2006, The Lancet.

[42]  Ted Cohen,et al.  Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness , 2004, Nature Medicine.